FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011807805> ?p ?o ?g. }

• W2011807805 endingPage "771" @default.
• W2011807805 startingPage "766" @default.
• W2011807805 abstract "Treatment of Pseudomonas aeruginosa infections is increasingly challenging because of escalating resistance. Antimicrobial stewardship programs provide guidance for clinicians regarding use of the most appropriate antimicrobial at the right dose, duration, and route in addition to being cost-effective. Optimizing antimicrobial therapy by using pharmacokinetic/pharmacodynamic principles such as extending time above the MIC is 1 stewardship strategy to reduce antimicrobial resistance.The goal of this study was to evaluate our current dosing strategy for cefepime and the formulary carbapenem (imipenem) compared with meropenem and doripenem to determine the best dosing strategy for achieving maximal pharmacodynamic activity against an institution-specific population of P aeruginosa isolates.Consecutive, nonduplicate, blood (n = 39) or bronchial alveolar lavage (n = 25) isolates of P aeruginosa from adult, hospitalized (2009-2010) critically ill patients underwent MIC testing by using broth microdilution. A pharmacokinetic model was developed and used with Monte Carlo simulation to evaluate the ability of imipenem, meropenem, doripenem, and cefepime to achieve optimal bactericidal activity as varying doses infused over standard infusions (SIs; 0.5-1 hour) or prolonged infusions (PIs; 3-4 hours). A regimen was defined as optimal if the cumulative fraction response (CFR) was ≥90%.None of the imipenem regimens modeled as SI or PI achieved a CFR ≥90%. Meropenem at 1 to 2 g q8h PI achieved a CFR ≥90%. Doripenem 0.5, 1, or 2 g q8h PI achieved a CFR ≥90%. The only cefepime regimen that achieved a CFR ≥90% was 2 g q8h PI. Overall susceptibility rates to P aeruginosa were highest with cefepime (91%), followed by meropenem (83%), doripenem (78%), and imipenem (72%). Our antimicrobial stewardship programs recommended switching from imipenem to doripenem 0.5g q8h PI, which was 36% more costly in drug acquisition costs. Cefepime dosing was increased from 2 g q12h SI to 2 g q8h PI, a 52% increase in drug acquisition cost.Antimicrobial stewardship programs should consider pharmacodynamic modeling to select the optimal dosing strategies to guide therapy in an era of escalating antimicrobial resistance. Using the percent susceptibility alone can be misleading and ultimately the most expensive if the patient fails to respond." @default.
• W2011807805 created "2016-06-24" @default.
• W2011807805 creator A5078323821 @default.
• W2011807805 creator A5088741251 @default.
• W2011807805 date "2013-06-01" @default.
• W2011807805 modified "2023-10-02" @default.
• W2011807805 title "When Pharmacodynamics Trump Costs: An Antimicrobial Stewardship Program’s Approach to Selecting Optimal Antimicrobial Agents" @default.
• W2011807805 cites W1501112436 @default.
• W2011807805 cites W1964367328 @default.
• W2011807805 cites W2011920054 @default.
• W2011807805 cites W2034302582 @default.
• W2011807805 cites W2068772863 @default.
• W2011807805 cites W2078012027 @default.
• W2011807805 cites W2087210751 @default.
• W2011807805 cites W2098057508 @default.
• W2011807805 cites W2106729847 @default.
• W2011807805 cites W2109836588 @default.
• W2011807805 cites W2143024482 @default.
• W2011807805 cites W2165158988 @default.
• W2011807805 cites W2168908910 @default.
• W2011807805 doi "https://doi.org/10.1016/j.clinthera.2013.05.004" @default.
• W2011807805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23795574" @default.
• W2011807805 hasPublicationYear "2013" @default.
• W2011807805 type Work @default.
• W2011807805 sameAs 2011807805 @default.
• W2011807805 citedByCount "16" @default.
• W2011807805 countsByYear W20118078052013 @default.
• W2011807805 countsByYear W20118078052014 @default.
• W2011807805 countsByYear W20118078052015 @default.
• W2011807805 countsByYear W20118078052016 @default.
• W2011807805 countsByYear W20118078052018 @default.
• W2011807805 countsByYear W20118078052020 @default.
• W2011807805 countsByYear W20118078052021 @default.
• W2011807805 countsByYear W20118078052022 @default.
• W2011807805 countsByYear W20118078052023 @default.
• W2011807805 crossrefType "journal-article" @default.
• W2011807805 hasAuthorship W2011807805A5078323821 @default.
• W2011807805 hasAuthorship W2011807805A5088741251 @default.
• W2011807805 hasConcept C100406419 @default.
• W2011807805 hasConcept C111113717 @default.
• W2011807805 hasConcept C112705442 @default.
• W2011807805 hasConcept C126322002 @default.
• W2011807805 hasConcept C177713679 @default.
• W2011807805 hasConcept C2776040555 @default.
• W2011807805 hasConcept C2776685102 @default.
• W2011807805 hasConcept C2777050379 @default.
• W2011807805 hasConcept C2777288759 @default.
• W2011807805 hasConcept C2777821550 @default.
• W2011807805 hasConcept C2779375183 @default.
• W2011807805 hasConcept C2779631663 @default.
• W2011807805 hasConcept C2781413609 @default.
• W2011807805 hasConcept C2908647359 @default.
• W2011807805 hasConcept C4937899 @default.
• W2011807805 hasConcept C501593827 @default.
• W2011807805 hasConcept C71924100 @default.
• W2011807805 hasConcept C86803240 @default.
• W2011807805 hasConcept C89423630 @default.
• W2011807805 hasConcept C94665300 @default.
• W2011807805 hasConcept C98274493 @default.
• W2011807805 hasConcept C99454951 @default.
• W2011807805 hasConceptScore W2011807805C100406419 @default.
• W2011807805 hasConceptScore W2011807805C111113717 @default.
• W2011807805 hasConceptScore W2011807805C112705442 @default.
• W2011807805 hasConceptScore W2011807805C126322002 @default.
• W2011807805 hasConceptScore W2011807805C177713679 @default.
• W2011807805 hasConceptScore W2011807805C2776040555 @default.
• W2011807805 hasConceptScore W2011807805C2776685102 @default.
• W2011807805 hasConceptScore W2011807805C2777050379 @default.
• W2011807805 hasConceptScore W2011807805C2777288759 @default.
• W2011807805 hasConceptScore W2011807805C2777821550 @default.
• W2011807805 hasConceptScore W2011807805C2779375183 @default.
• W2011807805 hasConceptScore W2011807805C2779631663 @default.
• W2011807805 hasConceptScore W2011807805C2781413609 @default.
• W2011807805 hasConceptScore W2011807805C2908647359 @default.
• W2011807805 hasConceptScore W2011807805C4937899 @default.
• W2011807805 hasConceptScore W2011807805C501593827 @default.
• W2011807805 hasConceptScore W2011807805C71924100 @default.
• W2011807805 hasConceptScore W2011807805C86803240 @default.
• W2011807805 hasConceptScore W2011807805C89423630 @default.
• W2011807805 hasConceptScore W2011807805C94665300 @default.
• W2011807805 hasConceptScore W2011807805C98274493 @default.
• W2011807805 hasConceptScore W2011807805C99454951 @default.
• W2011807805 hasIssue "6" @default.
• W2011807805 hasLocation W20118078051 @default.
• W2011807805 hasLocation W20118078052 @default.
• W2011807805 hasOpenAccess W2011807805 @default.
• W2011807805 hasPrimaryLocation W20118078051 @default.
• W2011807805 hasRelatedWork W1720517915 @default.
• W2011807805 hasRelatedWork W1938807169 @default.
• W2011807805 hasRelatedWork W2011807805 @default.
• W2011807805 hasRelatedWork W2061035147 @default.
• W2011807805 hasRelatedWork W2105640536 @default.
• W2011807805 hasRelatedWork W2145445190 @default.
• W2011807805 hasRelatedWork W2159108557 @default.
• W2011807805 hasRelatedWork W2285087135 @default.
• W2011807805 hasRelatedWork W3031323178 @default.
• W2011807805 hasRelatedWork W4311748752 @default.
• W2011807805 hasVolume "35" @default.

• next